{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:06:28Z","timestamp":1784541988405,"version":"3.55.0"},"reference-count":55,"publisher":"The Endocrine Society","issue":"3","funder":[{"DOI":"10.13039\/100005709","name":"Endocrine Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005709","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Hypercalcemia is a common complication of malignancy that is associated with high morbidity and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To support development of the Endocrine Society Clinical Practice Guideline for the treatment of hypercalcemia of malignancy in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched multiple databases for studies that addressed 8 clinical questions prioritized by a guideline panel from the Endocrine Society. Quantitative and qualitative synthesis was performed. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess certainty of evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We reviewed 1949 citations, from which we included 21 studies. The risk of bias for most of the included studies was moderate. A higher proportion of patients who received bisphosphonate achieved resolution of hypercalcemia when compared to placebo. The incidence rate of adverse events was significantly higher in the bisphosphonate group. Comparing denosumab to bisphosphonate, there was no significant difference in the rate of patients who achieved resolution of hypercalcemia. Two-thirds of patients with refractory\/recurrent hypercalcemia of malignancy who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia. Addition of calcitonin to bisphosphonate therapy did not affect the resolution of hypercalcemia, time to normocalcemia, or hypocalcemia. Only indirect evidence was available to address questions on the management of hypercalcemia in tumors associated with high calcitriol levels, refractory\/recurrent hypercalcemia of malignancy following the use of bisphosphonates, and the use of calcimimetics in the treatment of hypercalcemia associated with parathyroid carcinoma. The certainty of the evidence to address all 8 clinical questions was low to very low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The evidence summarized in this systematic review addresses the benefits and harms of treatments of hypercalcemia of malignancy. Additional information about patients\u2019 values and preferences, and other important decisional and contextual factors is needed to facilitate the development of clinical recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac631","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:44:41Z","timestamp":1671695081000},"page":"585-591","source":"Crossref","is-referenced-by-count":17,"title":["A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-4264","authenticated-orcid":false,"given":"Mohamed O","family":"Seisa","sequence":"first","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-5537","authenticated-orcid":false,"given":"Tarek","family":"Nayfeh","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Hasan","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Firwana","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Saadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mushannen","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahrish H","family":"Shah","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora S","family":"Rajjoub","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdoleen H","family":"Farah","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J","family":"Prokop","sequence":"additional","affiliation":[{"name":"Mayo Clinic Libraries , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada El-Hajj","family":"Fuleihan","sequence":"additional","affiliation":[{"name":"Calcium Metabolism and Osteoporosis Program, American University of Beirut , Beirut , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-7345","authenticated-orcid":false,"given":"Matthew T","family":"Drake","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Mayo Clinic , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-5975","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Mayo Clinic Evidence-Based Practice Center , Rochester, MN 55902 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"12","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm Metab Res"},{"issue":"5","key":"2023021518392941600_","first-page":"496","article-title":"Hypercalcemia of malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J Adv Practitioner Oncol"},{"issue":"15","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ecl.2021.07.003","article-title":"Hypercalcemia of malignancy","volume":"50","author":"Hu","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"North Am J Med Sci"},{"issue":"1","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Seminars Nephrol"},{"issue":"7","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ecl.2021.08.002","article-title":"Treatment of hypercalcemia of malignancy","volume":"50","author":"Chakhtoura","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clon.2004.03.008","article-title":"Bisphosphonate use in metastatic breast cancer: an audit assessing implementation of the British Association of Surgical Oncologists\u2019 Guidelines","volume":"16","author":"Abson","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.revmed.2010.11.007","article-title":"[Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma]","volume":"32","author":"Brantus","year":"2011","journal-title":"Rev Med Interne"},{"issue":"Suppl 3","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s12094-016-1590-1","article-title":"SEOM clinical guideline for bone metastases from solid tumours","volume":"18","author":"Gr\u00e1valos","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee","year":"2017","journal-title":"Intern Med J"},{"key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","article-title":"ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases","volume":"173","author":"Oldenburger","year":"2022","journal-title":"Radiother Oncol"},{"issue":"15","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-19-3797","article-title":"Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines","volume":"26","author":"Tischkowitz","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","author":"Wei","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"2023021518392941600_","author":"Transparent Reporting of Systematic Reviews and Meta-Analysis"},{"key":"2023021518392941600_","author":"Seisa","year":"19 , 2022"},{"key":"2023021518392941600_","author":"The Newcastle-Ottawa Scale"},{"key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/clinem\/dgac290","article-title":"Enhancing the trustworthiness of the Endocrine Society's Clinical Practice Guidelines","volume":"107","author":"McCartney","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","article-title":"A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system","volume":"93","author":"Swiglo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Arch Intern Med"},{"issue":"2","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(87)90487-6","article-title":"Etidronate disodium in the management of malignancy-related hypercalcemia","volume":"82","author":"Hasling","year":"1987","journal-title":"Am J Med"},{"issue":"4-5","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0959-8049(92)90143-P","article-title":"Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases\u2013a prospective randomised placebo-controlled multicentre study","volume":"28","author":"Rotstein","year":"1992","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"3","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archinte.1991.00400030039007","article-title":"Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group","volume":"151","author":"Singer","year":"1991","journal-title":"Arch Intern Med"},{"key":"2023021518392941600_","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2022.2115840","article-title":"Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma","author":"Lei","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"16","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"8","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1177\/1078155218820927","article-title":"Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: a retrospective cohort study","volume":"25","author":"Nasser","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thoracic Oncol"},{"issue":"35","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clml.2014.07.005","article-title":"Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction","volume":"14","author":"Cicci","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","article-title":"Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism","volume":"35","author":"Takeuchi","year":"2017","journal-title":"J Bone Mineral Metab"},{"issue":"10","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"issue":"4","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00223-022-01002-x","article-title":"Incidence of post-denosumab rebound hypercalcaemia in bony-metastatic breast cancer","volume":"111","author":"Wang","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2023021518392941600_","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"issue":"5","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0885066613507530","article-title":"Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy","volume":"30","author":"Maier","year":"2015","journal-title":"J Intensive Care Med"},{"issue":"2","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023021518392941600_","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"2023021518392941600_","author":"Zoledronic acid approval by FDA"},{"key":"2023021518392941600_","author":"Denosumab approval by FDA"},{"key":"2023021518392941600_","article-title":"Patient values and other decisional factors regarding treatment of hypercalcemia of malignancy: a novel mixed methods study","author":"Bassatne","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"2023021518392941600_","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline","author":"El-Hajj Fuleihan","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac631\/48869206\/dgac631.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/585\/49201115\/dgac631.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/585\/49201115\/dgac631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T19:23:11Z","timestamp":1679167391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/3\/585\/6916875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,2,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac631","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,12,21]]}}}